Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arzneiwerk AG VIDAFRA:TLIK +0.98%40 EBIT per Share is €-0.04 as of Mar. 2026. GuruFocus rates FRA:TLIK with a GF Score™ of 40/100. The stock has 7 warning signs investors should review. Among 104 Medical Distribution companies, Arzneiwerk AG VIDA ranks better than 84.62% on this metric.
Arzneiwerk AG VIDA's EBIT per Share for the
three
months ended in Mar. 2026 was €0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.04.
During the past 3 years, the average EBIT per Share Growth Rate was 37.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -24.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Arzneiwerk AG VIDA's EBIT per Share or its related term are showing as below:
FRA:TLIK'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -131.8 Med: 18.1 Max: 60.3
Current: 37.4
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Arzneiwerk AG VIDA was 60.30% per year. The lowest was -131.80% per year. And the median was 18.10% per year.
FRA:TLIK's 3-Year EBIT Growth Rate is ranked better than 84.62% of 104
companies
in the Medical Distribution industry
Industry Median: 4.1
vs FRA:TLIK: 37.40
Arzneiwerk AG VIDA (FRA:TLIK) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Arzneiwerk AG VIDA EBIT per Share Related Terms
Arzneiwerk AG VIDA EBIT per Share Historical Data
* Premium members only.
The historical data trend for Arzneiwerk AG VIDA's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.04
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arzneiwerk AG VIDA (FRA:TLIK) has a EBIT per Share of €-0.04 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Arzneiwerk AG VIDA and its competitors. According to the industry distribution chart, Arzneiwerk AG VIDA ranks #16 out of 104 companies in the Medical Distribution industry, placing it in the top 15.4%.
Is Arzneiwerk AG VIDA's EBIT per Share too high?
Arzneiwerk AG VIDA's current EBIT per Share is €-0.04. Based on the distribution chart, Arzneiwerk AG VIDA ranks #16 out of 104 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Arzneiwerk AG VIDA has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Arzneiwerk AG VIDA's EBIT per Share compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Arzneiwerk AG VIDA ranks #16 out of 104 companies for EBIT per Share. This places Arzneiwerk AG VIDA in the top 15% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 4.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Distribution company?
The median EBIT per Share among Medical Distribution companies is 4.10, based on 104 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Arzneiwerk AG VIDA and its competitors. For the Medical Distribution industry, the median EBIT per Share is 4.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arzneiwerk AG VIDA's current EBIT per Share is €-0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arzneiwerk AG VIDA stock overvalued right now?
Arzneiwerk AG VIDA (FRA:TLIK) has a current EBIT per Share of €-0.04. The current EBIT per Share is €-0.04. Arzneiwerk AG VIDA's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Arzneiwerk AG VIDA (FRA:TLIK), the current EBIT per Share is €-0.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Arzneiwerk AG VIDA is active in the pharmaceutical industry. The Pharma segment combines pharmaceutical supply with a focus on digitalization and process optimization along the pharmaceutical value chains and the management of large data volumes in the pharmaceutical industry. The company focuses on the growth area of specialty pharma in Germany and Europe.
40GF Score
Get the complete analysis for FRA:TLIK
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TLIK has been successfully added to your 
